U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H23N3O4S
Molecular Weight 341.426
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVOSULPIRIDE

SMILES

CCN1CCC[C@H]1CNC(=O)C2=CC(=CC=C2OC)S(N)(=O)=O

InChI

InChIKey=BGRJTUBHPOOWDU-NSHDSACASA-N
InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1

HIDE SMILES / InChI

Description

Levosulpiride [RV 12309, L-sulpiride, levosulpride, Dislep® 25, Levopride®, Levopraid®] is a potent dopamine D2 receptor blocker that was originated by Ravizza Farmaceutici (now AbbVie). Levosulpiride is the levo enantiomer of sulpiride. The levo enantiomer shows better/similar pharmacological actions and lower incidence of toxic effects than both dextro as well as the racemic forms of the drug. Levosulpiride is marketed in Italy and South Korea, and is possibly available elsewhere in Europe and Asia. Levosulpiride does not appear to be available in North America. Levosulpiride is available as 25mg tablets, drops and in ampoules for parenteral administration. Generic versions of levosulpiride also appear to be available in some countries. Levosulpiride is primarily indicated in conditions like Anxiety, Depression, Gastro-esophageal reflux disease, Irritable bowel syndrome, Schizophrenia, Tourette's syndrome, dyspeptic syndrome, essential cephalgia, and can also be given in adjunctive therapy as an alternative drug of choice in Peptic ulcer, Vertigo.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
51.0 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Levopraid
Primary
Unknown
Primary
Levopraid
Primary
Levopraid
Primary
Unknown

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
dosage depends on indication: 200 to 800 mg, 24 hourly, IM; 200 to 400 mg, 12 hourly, PO; 25 mg, 8 hourly, PO
Route of Administration: Other
In Vitro Use Guide
Unknown